Is baclofen contraindicated in patients with cirrhosis?

Baclofen is NOT contraindicated in cirrhosis, but requires careful patient selection and monitoring

Baclofen can be safely used in patients with compensated cirrhosis (Child-Pugh A/B) for alcohol use disorder, but should be avoided or used with extreme caution in decompensated cirrhosis (Child-Pugh C) due to increased risk of hepatic encephalopathy.

FDA Label Position

The FDA label for baclofen lists only hypersensitivity as a contraindication—cirrhosis is not mentioned 1. However, the approved indication is limited to spasticity from multiple sclerosis and spinal cord conditions, not alcohol use disorder 1.

Guideline Recommendations by Cirrhosis Severity

Compensated Cirrhosis (Child-Pugh A/B)

Multiple guidelines support baclofen use in this population:

• KASL 2013 & 2018 guidelines explicitly state that baclofen effectively maintained abstinence in cirrhotic patients over 12 weeks, reducing alcohol craving without adverse effects 2, 3. The 2018 guideline notes baclofen "safely improved bilirubin levels and MELD scores" in alcoholic cirrhosis 3.

• EASL 2018 guidelines acknowledge baclofen as "the only alcohol pharmacotherapy tested in patients with AUD with significant liver disease," demonstrating safety and efficacy in promoting abstinence in patients with alcoholic liver disease and cirrhosis 4. However, they note confirmatory studies are warranted and recommend not exceeding 80 mg/day per French regulatory guidance.

Decompensated Cirrhosis (Child-Pugh C)

This is where caution is critical:

• French 2023 guidelines recommend contraindication for benzodiazepines in decompensated cirrhosis 5, and while baclofen isn't explicitly contraindicated, the concern about precipitating hepatic encephalopathy applies.

• EASL 2025 guidelines note that short/intermediate-acting benzodiazepines are safer than long-acting ones in hepatic dysfunction, but baclofen is mentioned as an alternative for alcohol withdrawal syndrome 6.

Recent High-Quality Evidence: A Critical Warning

The most recent and concerning study (2026) found baclofen associated with significantly higher risk of major adverse liver outcomes compared to acamprosate in compensated alcohol-associated cirrhosis 7:

• 34.3% vs 27.4% incidence of hepatic decompensation at 1 year (HR 1.32)
• 1.8-fold increased risk of hepatic encephalopathy (HR 1.80,95% CI 1.21-2.69)
• Greater risk in patients aged 56-70 years

This contradicts earlier positive studies but represents the largest real-world comparative safety analysis.

Reconciling Contradictory Evidence

Earlier studies showed benefit:

• 2007 RCT: 71% abstinence with baclofen vs 29% placebo in cirrhotic patients, well-tolerated 8
• 2017-2023 observational studies: Good tolerability, improved liver function markers 9, 10
• 2023 meta-analysis: 53% overall abstinence rate, no addiction cases 11

However, the 2026 comparative study's findings of increased hepatic encephalopathy risk cannot be ignored and represents the most methodologically rigorous safety comparison.

Clinical Algorithm for Baclofen Use in Cirrhosis

Step 1: Assess Cirrhosis Severity

• Child-Pugh A: Can consider baclofen with close monitoring
• Child-Pugh B: Use only with extreme caution; acamprosate preferred
• Child-Pugh C or decompensated: Avoid baclofen—use acamprosate instead

Step 2: Screen for Contraindications

• Current hepatic encephalopathy: Absolute contraindication
• Age >56 years: Higher risk per recent data 7
• Renal impairment: Baclofen is renally cleared; dose adjustment needed
• Ascites: Increased risk of complications

Step 3: If Proceeding with Baclofen

• Start low: 15-30 mg/day divided doses
• Maximum dose: 80 mg/day (per French regulatory guidance) 4
• Never exceed this dose in cirrhotic patients
• Monitor every 2-4 weeks initially for:
  • Mental status changes (early encephalopathy)
  • Liver function tests
  • Renal function

Step 4: Preferred Alternative

Acamprosate is safer in cirrhosis because it's renally cleared and showed lower decompensation risk 7. Use 1,998 mg/day if weight ≥60 kg, reduced by one-third if <60 kg 2.

Critical Pitfalls to Avoid

1. Don't confuse "not contraindicated" with "safe"—the 2026 data shows real harm signal
2. Don't use baclofen as first-line in any cirrhotic patient—acamprosate is safer
3. Don't ignore subtle mental status changes—may herald encephalopathy
4. Don't use in patients with prior encephalopathy episodes
5. Don't combine with benzodiazepines in decompensated patients 5

Bottom Line

While older guidelines supported baclofen in cirrhosis based on small studies, the most recent 2026 comparative evidence shows increased hepatic encephalopathy risk 7. Baclofen is not formally contraindicated but should be reserved for compensated cirrhosis (Child-Pugh A) when acamprosate fails or is contraindicated, with doses ≤80 mg/day and intensive monitoring. In decompensated cirrhosis, avoid baclofen entirely.